SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today reported that the Company’s study results demonstrating that its Acute Radiation Syndrome (ARS) drug candidate, NEUMUNE® (HE2100), significantly improved survival in clinically unsupported rhesus monkeys with radiation-induced myelosuppression, is being published in the April 2007 issue of International Immunopharmacology and is now available on-line at http://dx.doi.org/10.1016/j.intimp.2006.12.005. The Company believes the published data represent the first instance where a compound administered as a single agent after exposure favorably affected survival in lethally irradiated, clinically unsupported non-human primates. In the event of a nuclear mass-casualty event, a stand-alone therapy not requiring supportive clinical care would be critical for improving survival among first responders, healthcare providers, military personnel and the general public.
